Preclinical Development of a First-in-Class PCNA Inhibitor for Treating Neuroblastoma |
City of Hope National Medical Center / Linda Malkas, PhD |
Reach Grants |
2019 |
California |
Optimization of Drug Efflux and Brain Clearance to Improve CED of Targeted Therapy to H3K27M DMG |
Mayo Clinic / David Daniels, MD/PhD |
Reach Grants |
2021 |
Minnesota |
Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias |
National Cancer Institute / Andre Nussenzweig, Ph.D. |
Reach Grants |
2014 |
Maryland |
Novel Genomic Diagnostics for Intracranial Germ Cell Tumors |
Connecticut Children’s Medical Center Foundation, Inc. / Ching Lau, MD/PhD |
Reach Grants |
2021 |
Connecticut |
Identification of Rhabdomyosarcoma Therapies Using an Efficient Mouse and Drosophila Repurposing Screen |
Memorial Sloan-Kettering Cancer Center / Mary Baylies, Ph.D. |
Reach Grants |
2014 |
New York |
Astatine-211 Meta-Astatobenzylguanidine ([211At]MABG) Targeted Radiotherapy for Disseminated Neuroblastoma |
Children’s Hospital of Philadelphia / John Maris, MD |
Reach Grants |
2016 |
Pennsylvania |
Generation of CMV-specific CD19 CAR T cells Using Cytokine Capture Followed by Lentiviral Transduction and Expansion |
Research Institute at Nationwide Children's Hospital / Margaret Lamb, MD |
Reach Grants |
2019 |
Ohio |
Targeting PLK1 as a Common Mechanism in Ph-like ALL |
University of Texas M.D. Anderson Cancer Center / Joya Chandra, PhD |
Reach Grants |
2016 |
Texas |
Immunotherapy for Pediatric Atypical Teratoid/Rhabdoid Tumor |
Baylor College of Medicine / William Decker, PhD |
Reach Grants |
2013 |
Texas |
B-lapachone as a Novel Targeted Therapy for ATRTs and other Pediatric Cancers
|
University of Texas Southwestern Medical Center / James Amatruda, MD, PhD |
Reach Grants |
2013 |
Texas |